Long-Term Cost-Effectiveness of Ideglira Versus Basal-Bolus Insulin As Intensification Therapies For People With Type 2 Diabetes Inadequately Controlled on Basal Insulin In Spain: Projections Based On The Dual VII Trial

Ampudia, FJ; Mezquita, P.; Arellano, A Ramirez de; Basse, A; Hunt, Barnaby

doi:10.1016/j.jval.2017.08.461

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with other published health economic analyses of IDegLira. Cost‐effectiveness evaluations based on clinical trial data on IDegLira have shown that it is likely to improve clinical outcomes and be cost‐effective versus several comparator regimens (basal insulin, basal‐bolus insulin, and GLP‐1 receptor agonists in combination with insulin) in patients with type 2 diabetes in the United States, the Netherlands, the Czech Republic, Sweden, the United Kingdom and Spain . Comparable health economic outcomes from the present study based on real‐world evidence are reassuring, as they indicate that the benefits of IDegLira observed in RCTs translate to the real‐world setting, and that similar improvements in long‐term outcomes with IDegLira can be anticipated for patients in routine clinical practice.…”

Section: Discussionsupporting

confidence: 55%

Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence

Raya

Ampudia‐Blasco

Hunt³

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim To evaluate the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on real‐world evidence. Materials and methods Clinical data were taken from the European Xultophy Treatment Retrospective Audit (EXTRA) real‐world evidence study in which patients failing to meet glycaemic targets were switched to IDegLira. Baseline regimens (prior to IDegLira treatment) were categorized as: multiple daily insulin injections (MDI; 28%); glucagon‐like peptide‐1 (GLP‐1) receptor agonists in combination with insulin (24%); basal insulin (19%); GLP‐1 receptor agonists (10%); and non‐injectable medications (19%). The IQVIA CORE Diabetes Model was used to project long‐term outcomes for patients switching to IDegLira or continuing their baseline regimens (excluding non‐injectable regimens). Costs were accounted from a Spanish National Health System perspective. Future costs and clinical benefits were discounted at 3% annually and sensitivity analyses were performed. Results IDegLira was projected to reduce the incidence of diabetes‐related complications and improve quality‐adjusted life expectancy versus all four comparators. IDegLira reduced direct medical costs versus GLP‐1 receptor agonists in combination with insulin, and versus GLP‐1 receptor agonist therapy, and was therefore considered dominant (cost saving while improving outcomes). IDegLira was found to be cost‐effective versus MDI and basal insulin with incremental cost‐effectiveness ratios of EUR 3013 per quality‐adjusted life‐year (QALY) gained and EUR 6890 per QALY gained, respectively. Conclusions Long‐term projections based on real‐world evidence indicated that IDegLira is likely to improve clinical outcomes and reduce costs or be cost‐effective compared with other injectable regimens in people with type 2 diabetes in Spain.

show abstract

Section: Discussionsupporting

confidence: 55%